8 
Fallowing a brief recess, Er. Iblin proposed compromise language. Section 
VII-D-6 would be amended to read in part: 
"... so that the spaoe above the culture level will be maintained 
at a pressure as low as possible, consistent with equipment design, 
in order to maintain the integrity of containment features." 
Dr. McKinney called the vote on this language. By a vote of five in favor, 
none opposed, and no abstentions, the language was accepted by the working 
group. Dr. McKinney said the proposed amendment to Section VII-D-6 of the 
Physical Containment Recommendations for Large-Scale Uses of Organisms 
Containing Recombinant DMA Molecules would be forwarded to the Recombinant 
DNA Advisory Committee (RAC) for their consideration. 
Proposal to Amend Section III-B-5 of the Guideline s 
Dr. McKinney then introduced Dr. Allan Waitz of DNAX Research Institute of 
Molecular and Cellular Biology, a wholly owned subsidiary of Schering-Plough 
Corporation. Dr. Waitz said Schering-Plough Corporation is committed to doing 
business in a way that ensures safety for the environment, the canminity, and 
the workers, and believes adherence to the NIH Guidelines for Research 
Involving Recombinant ENA Molecules is an important aspect of that commitment. 
Schering-Plough Corporation believes that compliance with the NIH Guidelines 
is reassuring to the ccmminities in which Schering-Plough facilities are located 
and this benefits the technology as a whole. Dr. Waitz said Schering-Plough 
Corporation has voluntarily complied with the NIH Guidelines in facilities 
in Omaha, Nebraska, and Bloomfield and Uhion, New Jersey, as well as in 
r 45] 
